UCL spinout Octopath AI raises £1.5m led by TwinPath Ventures with Innovate UK
This article covers Octopath AI, a UCL spinout healthtech startup that has raised £1.5m in a seed funding round, including a £500k Innovate UK grant, to develop AI-powered digital pathology models. The funding will support clinical evaluation, product development and regulatory work aimed at providing pathologists with quantitative measurements from routine tissue slides to help relieve pressure on pathology services.
Octopath AI, a UCL spinout healthtech startup, has raised £1.5m in a seed funding round combining private investment and grant support to develop its AI-powered digital pathology models that extract more information from routine tissue slides. The capital will fund clinical evaluation, product development and steps towards regulatory approval at a time when pathology services are under acute pressure.
Why it matters
Pathology is a bottleneck in cancer diagnosis. In May 2026 more than 55,000 people in England waited longer than the NHS four-week standard to learn whether they had cancer, and only 3% of UK histopathology departments report having enough staff to meet demand. Tools that can produce reliable measurements from every slide, faster, could ease that burden and change how diagnostic workflows scale.
Octopath AI aims to provide pathologists with quantitative data — cell counts, densities and spatial relationships — that would be impractical to capture manually. If adopted, the technology could help speed case reviews, support biomarker scoring and feed more consistent data into clinical trials and research.
Inside the product
The company’s models, named Kraken and Nemo, analyse routine stained tissue slides at single-cell resolution in under two minutes per slide. Octopath AI says the platform measures every cell rather than relying on samples from selected areas and that the models were trained on more than 14 million individually labelled cells across 14 cancer types.
Training used spatial-omics data, which records molecules such as RNA and proteins while preserving their location inside tissue. Reported use cases include tumour grading, immune-cell mapping, cellularity assessment, blood‑vessel analysis and biomarker scoring. By contrast, the press release notes that a manual estimate of tumour cell density typically takes around 20 minutes per slide.
The platform is already deployed at five sites, including University College London Hospitals where it is processing about 200 anonymised slides a day. Samples from four clinical trials are also being assessed as part of ongoing testing.
Who are the investors?
The raise was led by TwinPath Ventures and includes a £500,000 Innovate UK grant that was unlocked on a matched basis by the investment, bringing the combined total to £1.5m. UCL Ventures supported the team to protect the research, identify the market opportunity and introduce the founders to investors.
The funding is earmarked for clinical evaluation, product development and regulatory work. The combination of private capital and Innovate UK backing reflects both venture interest and public funding priorities in diagnostic innovation.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Dr Esther Bär, co-founder and Chief Executive Officer of Octopath AI, said:
Pathologists are being asked to do more with the same slides and the same hours. The information we need is already there on the glass; it just never comes off it.
We built Octopath AI to get it out, in a form pathologists can trust and act on, without adding to their day.
In the announcement, Dr Anne Lane, Chief Executive Officer of UCL Ventures, said:
Octopath AI is a powerful example of UCL research being translated into a company with the potential to improve both patient care and the resilience of health services.
UCL Ventures’ business manager Billy Lam is listed as supporting the commercialisation pathway, including IP strategy and translational planning for medtech and AI-enabled healthcare innovations.
The bigger picture
Octopath AI’s seed round sits within a broader push to apply AI in diagnostic workflows and to secure earlier clinical validation for medical AI products. The mixed funding model — private lead investment plus matched Innovate UK grant — is a common route for early-stage healthtech firms navigating clinical studies and regulatory labs.
For the NHS and UK research hospitals under capacity strain, tools that can efficiently surface robust, reproducible measurements from existing slides are attractive. The next milestones for Octopath AI will be demonstrable clinical utility, regulatory clearance and wider adoption by pathology services. The deal underlines continuing investor interest in UK healthtech and the role of public funds in de‑risking early clinical development.
They've invested in Octopath AI
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Twin Path Ventures( ) Twin Path Ventures is a venture capital firm focused on investing in AI-first st... London  | ||||
 | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK